Andrew Schiermeier

Andrew Schiermeier is an accomplished executive in the biotechnology and pharmaceutical industries, currently serving as Chief Executive Officer at AvenCell since August 2021, focusing on innovative Engineered Cell Therapies. Prior to this, Schiermeier was the Chief Operating Officer at Intellia Therapeutics, Inc., where responsibilities included overseeing eXtellia and developing applications for CRISPR/Cas9 technology in immuno-oncology and autoimmune disorders. Schiermeier held key positions at Merck KGaA as SVP and Global Head of Oncology and led the international not-for-profit organization Medicine in Need (MEND) as Chairman. Additional roles included corporate advisor at Pathogenica, COO at Aura BioSciences, and CEO at Lantibio, Inc. Schiermeier possesses extensive academic credentials with a Ph.D. in Engineering & Applied Math from Harvard University, an MBA in Finance and Strategy from College des Ingenieurs, and a wealth of experience across various leadership positions.